Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,027 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MicroRNA-451a inhibits gemcitabine-refractory biliary tract cancer progression by suppressing the MIF-mediated PI3K/AKT pathway.
Obata T, Tsutsumi K, Ueta E, Oda T, Kikuchi T, Ako S, Fujii Y, Yamazaki T, Uchida D, Matsumoto K, Horiguchi S, Kato H, Okada H, Otsuka M. Obata T, et al. Among authors: kikuchi t. Mol Ther Nucleic Acids. 2023 Oct 28;34:102054. doi: 10.1016/j.omtn.2023.102054. eCollection 2023 Dec 12. Mol Ther Nucleic Acids. 2023. PMID: 38111913 Free PMC article.
Cysts or necrotic components in pancreatic ductal adenocarcinoma is associated with the risk of EUS-FNA/B complications including needle tract seeding.
Terasawa H, Matsumoto K, Tanaka T, Tomoda T, Ogawa T, Ishihara Y, Kikuchi T, Obata T, Oda T, Matsumi A, Miyamoto K, Morimoto K, Fujii Y, Yamazaki T, Uchida D, Horiguchi S, Tsutsumi K, Kato H, Otsuka M. Terasawa H, et al. Among authors: kikuchi t. Pancreatology. 2023 Dec;23(8):988-995. doi: 10.1016/j.pan.2023.10.018. Epub 2023 Oct 28. Pancreatology. 2023. PMID: 37951728
Predictive factors for transition to conversion therapy in hepatocellular carcinoma using atezolizumab plus bevacizumab.
Kikuchi T, Takeuchi Y, Nouso K, Kariyama K, Kuwaki K, Toshimori J, Iwado S, Moriya A, Hagihara H, Takabatake H, Tada T, Yasunaka T, Sakata M, Sue M, Miyake N, Adachi T, Wada N, Onishi H, Shiraha H, Takaki A, Otsuka M. Kikuchi T, et al. Liver Int. 2024 Jun;44(6):1456-1463. doi: 10.1111/liv.15907. Epub 2024 Mar 15. Liver Int. 2024. PMID: 38488749
MicroRNA-34a-5p: A pivotal therapeutic target in gallbladder cancer.
Oda T, Tsutsumi K, Obata T, Ueta E, Kikuchi T, Ako S, Fujii Y, Yamazaki T, Uchida D, Matsumoto K, Horiguchi S, Kato H, Okada H, Chijimatsu R, Otsuka M. Oda T, et al. Among authors: kikuchi t. Mol Ther Oncol. 2024 Feb 8;32(1):200765. doi: 10.1016/j.omton.2024.200765. eCollection 2024 Mar 21. Mol Ther Oncol. 2024. PMID: 38596294 Free PMC article.
Response to the letter: "Predictive factors for transition to conversion therapy in HCC using atezolizumab plus bevacizumab".
Kikuchi T, Takeuchi Y, Nouso K, Kariyama K, Kuwaki K, Toshimori J, Iwado S, Moriya A, Hagihara H, Takabatake H, Tada T, Yasunaka T, Sakata M, Sue M, Miyake N, Adachi T, Wada N, Onishi H, Shiraha H, Takaki A, Otsuka M. Kikuchi T, et al. Liver Int. 2024 Jul;44(7):1736-1737. doi: 10.1111/liv.15964. Epub 2024 May 8. Liver Int. 2024. PMID: 38717049 No abstract available.
The prediction of early progressive disease in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab.
Takeuchi Y, Nouso K, Fujioka SI, Kariyama K, Kobashi H, Uematsu S, Moriya A, Hagihara H, Takabatake H, Nakamura S, Yabushita K, Kikuchi T, Oyama A, Adachi T, Wada N, Onishi H, Shiraha H, Takaki A. Takeuchi Y, et al. Among authors: kikuchi t. Cancer Med. 2023 Sep;12(17):17559-17568. doi: 10.1002/cam4.6369. Epub 2023 Aug 3. Cancer Med. 2023. PMID: 37537956 Free PMC article.
3,027 results